Trial Profile

A second adequate and well-controlled clinical Phase III Study of IMC-1 for the Treatment of Fibromyalgia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib/famciclovir (Primary)
Indications Fibromyalgia
Focus Registrational; Therapeutic Use

Most Recent Events

30 Oct 2024 According to Virios Therapeutics media release, Virios Therapeutics has changed its name to Dogwood Therapeutics.
10 Aug 2023 According to a Virios Therapeutics media release, the Company submitting a final Phase 3 program outline and associated Phase 3 study protocols for FDA review, this year.
19 May 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com